IRMD Fail-to-Deliver

IRadimed Corporation (IRMD) operates in the Healthcare sector, specifically the Medical - Devices industry, with a market capitalization near $1.20B, listed on NASDAQ, employing roughly 160 people, carrying a beta of 0.92 to the broader market. IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. Led by Roger E. Susi, public since 2014-07-16.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date
2026-06-12
Latest FTD Quantity
14
Latest Price
$96.26
30-Day Avg FTD
1.6K
30-Day Total FTD
48.1K

Showing 30 days of SEC fail-to-deliver data for IRadimed Corporation.

Learn how fails-to-deliver is reported and how to read the data →

Frequently asked IRMD fail to deliver questions

What is the latest IRMD fail-to-deliver count?
As of Jun 12, 2026, IRadimed Corporation (IRMD) fail-to-deliver quantity is 14 shares, with a 30-day average of 1.6K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
What is the FTD aggregate net balance?
FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
How do IRMD FTDs affect options pricing?
Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.